<!DOCTYPE html>
<html lang="en" class="scroll-smooth">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>In Silico Design of a Vaccine for Group A Streptococcus | Rakesh Kumar A</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Merriweather:ital,wght@0,400;0,700;1,400&family=Roboto:wght@400;500;700&family=Source+Serif+Pro:ital,wght@0,400;0,600;1,400&display=swap" rel="stylesheet">
    
    <!-- Favicon -->
    <link rel="icon" href="data:image/svg+xml,<svg xmlns=%22http://www.w3.org/2000/svg%22 viewBox=%220 0 100 100%22><text y=%22.9em%22 font-size=%2290%22>ðŸ§¬</text></svg>">

    <style>
        :root {
            --primary-color: #0d47a1; /* A deep, academic blue */
            --secondary-color: #6c757d;
            --accent-color: #1976d2;
            --background-color: #f8f9fa;
            --text-color: #212529;
            --light-gray: #e9ecef;
            --medium-gray: #ced4da;
        }
        
        body {
            font-family: 'Source Serif Pro', Georgia, serif;
            background-color: var(--background-color);
            color: var(--text-color);
            line-height: 1.7;
        }
        
        h1, h2, h3, h4, h5, h6 {
            font-family: 'Merriweather', Georgia, serif;
            color: var(--primary-color);
            font-weight: 700;
        }
        
        .journal-container {
            max-width: 1200px;
            margin: 0 auto;
            padding: 0 2rem;
        }
        
        .journal-header {
            text-align: center;
            padding: 3rem 0;
            border-bottom: 1px solid var(--medium-gray);
            margin-bottom: 2rem;
        }
        
        .journal-title {
            font-size: 2.5rem;
            margin-bottom: 1rem;
        }
        
        .authors {
            font-size: 1.1rem;
            color: var(--secondary-color);
            margin-bottom: 0.5rem;
        }
        
        .affiliation {
            font-size: 1rem;
            color: var(--secondary-color);
            font-style: italic;
        }
        
        .two-column {
            column-count: 2;
            column-gap: 2.5rem;
            text-align: justify;
        }

        @media (max-width: 768px) {
            .two-column {
                column-count: 1;
            }
        }
        
        .full-width {
            column-span: all;
        }
        
        .section-title {
            font-size: 1.75rem;
            margin: 3rem 0 1.5rem;
            column-span: all;
            border-bottom: 2px solid var(--primary-color);
            padding-bottom: 0.5rem;
        }
        
        .subsection-title {
            font-size: 1.25rem;
            margin: 1.5rem 0 1rem;
            font-weight: 600;
            color: #343a40;
        }
        
        .figure {
            margin: 2rem 0;
            break-inside: avoid;
            background: white;
            padding: 1.5rem;
            border-radius: 0.5rem;
            border: 1px solid var(--light-gray);
            box-shadow: 0 2px 4px rgba(0,0,0,0.05);
        }
        
        .figure-caption {
            font-size: 0.9rem;
            color: var(--secondary-color);
            margin-top: 1rem;
            text-align: left;
            line-height: 1.5;
        }
        
        .figure-number, .table-number {
            font-weight: 700;
            color: var(--primary-color);
        }

        .journal-table {
            width: 100%;
            border-collapse: collapse;
            margin: 1.5rem 0;
            font-size: 0.9rem;
        }
        
        .journal-table th {
            background-color: #f1f3f5;
            text-align: left;
            padding: 0.75rem;
            font-weight: 600;
        }
        
        .journal-table td {
            padding: 0.75rem;
            border-bottom: 1px solid var(--light-gray);
        }

        .references {
            padding-left: 1.5rem;
            text-indent: -1.5rem;
            font-size: 0.9rem;
            line-height: 1.6;
        }
        
        .reference-item {
            margin-bottom: 1rem;
        }

        .nav-link {
            transition: all 0.2s ease;
            border-bottom: 2px solid transparent;
            font-family: 'Roboto', sans-serif;
            padding-bottom: 0.25rem;
        }
        
        .nav-link.active, .nav-link:hover {
            color: var(--accent-color);
            border-bottom-color: var(--accent-color);
        }
    </style>
</head>
<body>
    <div class="journal-container">
        <header class="journal-header">
            <h1 class="journal-title">An In Silico Approach for Designing a Multi-Epitope Vaccine for Group A Streptococcus (GAS) Infection</h1>
            <div class="authors">Rakesh Kumar A<sup>1</sup></div>
            <div class="affiliation"><sup>1</sup>Department of Life Sciences, Garden City University, Bangalore, India</div>
        </header>
        
        <nav class="sticky top-0 z-50 bg-white/95 backdrop-blur-sm shadow-md py-3 px-6 mb-8 rounded-lg">
            <div class="hidden md:flex justify-center items-center space-x-8">
                <a href="#abstract" class="nav-link font-medium text-gray-600">Abstract</a>
                <a href="#introduction" class="nav-link font-medium text-gray-600">Introduction</a>
                <a href="#methods" class="nav-link font-medium text-gray-600">Methods</a>
                <a href="#results" class="nav-link font-medium text-gray-600">Results</a>
                <a href="#discussion" class="nav-link font-medium text-gray-600">Discussion</a>
                <a href="#conclusion" class="nav-link font-medium text-gray-600">Conclusion</a>
                <a href="#references" class="nav-link font-medium text-gray-600">References</a>
            </div>
            <div class="md:hidden">
                <select id="mobile-nav" class="w-full p-2 border rounded-md bg-gray-50">
                    <option value="#abstract">Abstract</option>
                    <option value="#introduction">Introduction</option>
                    <option value="#methods">Methods</option>
                    <option value="#results">Results</option>
                    <option value="#discussion">Discussion</option>
                    <option value="#conclusion">Conclusion</option>
                    <option value="#references">References</option>
                </select>
            </div>
        </nav>

        <main>
            <section id="abstract">
                <h2 class="section-title full-width">Abstract</h2>
                <div class="bg-blue-50 p-6 rounded-lg border border-blue-200 text-justify">
                    <p class="mb-3">
                        Group A Streptococcus (GAS), or *Streptococcus pyogenes*, remains a significant global health threat, causing a wide spectrum of diseases from mild pharyngitis to severe, life-threatening conditions like necrotizing fasciitis and streptococcal toxic shock syndrome. Despite its prevalence, no licensed vaccine is currently available. This study details the computational design and validation of a multi-epitope subunit vaccine against GAS using an integrated immunoinformatics approach.
                    </p>
                    <p class="mb-3">
                        We identified highly immunogenic T-cell and B-cell epitopes from the M protein and FbaA protein, two critical GAS virulence factors. A 601-amino acid chimeric vaccine was constructed by linking these epitopes with appropriate linkers (EAAAK, AAY, GPGPG) and incorporating a 50S ribosomal protein L7/L12 as an adjuvant to enhance immunogenicity.
                    </p>
                    <p>
                        Comprehensive in silico analysis confirmed the construct to be antigenic, non-allergenic, and possess favorable physicochemical properties suggesting stability and solubility. Structural modeling and validation revealed a high-quality tertiary structure. Molecular docking demonstrated strong, stable binding interactions with key immune receptors (TLR4, MHC-I, MHC-II). Immune simulations predicted the induction of robust humoral and cell-mediated responses. Finally, codon optimization and in silico cloning confirmed the high potential for expression in *E. coli*. These findings suggest that our rationally designed vaccine is a promising candidate that warrants experimental validation.
                    </p>
                </div>
            </section>
            
            <section id="introduction">
                <h2 class="section-title">1. Introduction</h2>
                <div class="two-column">
                    <p class="mb-4">
                        *Streptococcus pyogenes*, also known as Group A Streptococcus (GAS), is a formidable human pathogen responsible for over 500,000 deaths annually worldwide. It causes a diverse array of diseases, ranging from common superficial infections like pharyngitis ("strep throat") and impetigo to severe, invasive diseases such as streptococcal toxic shock syndrome (STSS) and necrotizing fasciitis, which carry high mortality rates. Furthermore, post-streptococcal autoimmune sequelae, including acute rheumatic fever and glomerulonephritis, contribute significantly to the global burden of disease, particularly in low-resource settings.
                    </p>
                    <p class="mb-4">
                        The M protein is a major virulence factor of GAS, crucial for its ability to evade the host immune system. The FbaA protein is another key factor, facilitating fibronectin binding, which is essential for the pathogen's adherence to and invasion of host cells. The high variability of the M protein has been a major obstacle to traditional vaccine development, necessitating novel approaches that can provide broad protection.
                    </p>
                    <p class="mb-4">
                        In recent years, reverse vaccinology and immunoinformatics have emerged as powerful tools for rational vaccine design. This *in silico* approach allows for the rapid identification of promising antigenic candidates from genomic and proteomic data, bypassing the need to culture pathogens and significantly accelerating the preclinical development phase. By focusing on conserved and immunodominant epitopes, it is possible to design multi-epitope subunit vaccines that can elicit a targeted and robust immune response while minimizing the risk of allergenicity or adverse reactions.
                    </p>
                    <p class="mb-4">
                        This study employs a comprehensive immunoinformatics pipeline to design a multi-epitope vaccine against GAS. We targeted the M protein and FbaA protein to identify conserved T-cell and B-cell epitopes. These epitopes were then assembled into a single chimeric protein, fused with a potent adjuvant to boost its immunogenicity. The designed vaccine was subjected to extensive computational analysis, including evaluation of its physicochemical properties, structural modeling, molecular docking with immune receptors, and simulation of the resulting immune response. Our goal is to develop a promising vaccine candidate that is stable, safe, and capable of inducing a strong protective immune response against GAS.
                    </p>
                </div>
            </section>

            <section id="methods">
                <h2 class="section-title full-width">2. Materials and Methods</h2>
                <div class="two-column">
                    <h3 class="subsection-title full-width">2.1. Protein Retrieval and Epitope Prediction</h3>
                    <p class="mb-4">
                        The amino acid sequences for the M protein (UniProt ID: P12379.1) and FbaA protein (UniProt ID: Q93R11) of *S. pyogenes* were retrieved from the UniProt database. The Immune Epitope Database (IEDB) was utilized to predict potential T-cell epitopes binding to MHC class I and class II alleles. B-cell epitopes were also predicted. The predicted epitopes were screened for antigenicity using the VaxiJen v2.0 server, allergenicity using AllerTOP v2.0, and toxicity via the ToxinPred server. Only epitopes that were predicted to be antigenic, non-allergenic, and non-toxic were selected for vaccine construction.
                    </p>

                    <h3 class="subsection-title full-width">2.2. Vaccine Construction</h3>
                    <p class="mb-4">
                        A multi-epitope vaccine was designed by sequentially linking the selected epitopes. A 50S ribosomal protein L7/L12 adjuvant was added at the N-terminus, connected by an EAAAK linker. Cytotoxic T-lymphocyte (CTL) epitopes were joined using AAY linkers, while Helper T-lymphocyte (HTL) epitopes were connected with GPGPG linkers to maintain independent immunogenic presentation.
                    </p>

                    <h3 class="subsection-title full-width">2.3. Physicochemical and Structural Analysis</h3>
                    <p class="mb-4">
                        The physicochemical properties of the final vaccine construct, including molecular weight, theoretical pI, instability index, aliphatic index, and Grand Average of Hydropathicity (GRAVY), were computed using the ProtParam tool on the ExPASy server. The secondary structure was predicted using the PSIPRED server. The tertiary (3D) structure was modeled using the Robetta server. The quality and stereochemical properties of the 3D model were validated using MOLPROBITY, which generates a Ramachandran plot analysis.
                    </p>

                    <h3 class="subsection-title full-width">2.4. Molecular Docking</h3>
                    <p class="mb-4">
                        To evaluate the binding affinity of the vaccine with key immune receptors, protein-protein docking was performed using the HADDOCK v2.2 web server. The vaccine construct was docked with Toll-like receptor 4 (TLR4), MHC-I, and MHC-II molecules. The resulting complexes were analyzed for binding energy and interacting residues.
                    </p>

                    <h3 class="subsection-title full-width">2.5. Immune Simulation</h3>
                    <p class="mb-4">
                        An *in silico* immune simulation was performed using the C-ImmSim server to predict the immunogenic profile of the vaccine. The simulation was run with a three-injection schedule at four-week intervals to mimic a standard vaccination protocol. The server predicts the response of various immune cell populations (B-cells, T-cells) and cytokine levels over time.
                    </p>

                    <h3 class="subsection-title full-width">2.6. Codon Optimization and In Silico Cloning</h3>
                    <p class="mb-4">
                        The amino acid sequence of the vaccine was reverse-translated into a DNA sequence. This sequence was then codon-optimized for expression in the *E. coli* K12 strain using the Java Codon Adaptation Tool (JCAT) to ensure high-level protein expression. Finally, the optimized gene sequence was inserted into the pET28a(+) expression vector *in silico* using the SnapGene tool to generate a recombinant plasmid map.
                    </p>
                </div>
            </section>
            
            <section id="results">
                <h2 class="section-title full-width">3. Results</h2>
                <div class="two-column">
                    <h3 class="subsection-title full-width">3.1. Vaccine Construct and Physicochemical Properties</h3>
                    <p class="mb-4">
                        The final multi-epitope vaccine construct is a 601 amino acid chimeric protein. The physicochemical analysis predicted a molecular weight of 61.6 kDa and a theoretical pI of 6.08. The instability index was calculated to be 31.72, classifying the protein as stable. The aliphatic index of 62.33 suggests good thermostability, and the negative GRAVY score of -0.428 indicates that the protein is hydrophilic and likely to be soluble.
                    </p>
                    <div class="figure full-width">
                        <img src="images/vaccine-construct.png" alt="Vaccine Construct Diagram" class="rounded-lg w-full h-auto object-contain border">
                        <p class="figure-caption"><span class="figure-number">Figure 1.</span> Schematic of the final multi-epitope vaccine construct. The design includes an N-terminal adjuvant, followed by CTL epitopes (green) and HTL epitopes (orange/blue), connected by specific linkers to ensure proper immunogenic presentation.</p>
                    </div>

                    <h3 class="subsection-title full-width">3.2. Structural Validation</h3>
                    <p class="mb-4">
                        The 3D model of the vaccine, generated by the Robetta server, was validated using MOLPROBITY. The Ramachandran plot analysis showed that 94.16% of the amino acid residues were in the most favored regions, with an additional 4.67% in allowed regions. This indicates a high-quality, stereochemically favorable protein structure, which is crucial for its biological function and stability.
                    </p>
                    <div class="figure full-width">
                        <img src="images/3d-structure-validation.png" alt="3D Structure and Ramachandran Plot" class="rounded-lg w-full h-auto object-contain border">
                        <p class="figure-caption"><span class="figure-number">Figure 2.</span> The predicted tertiary structure of the vaccine construct (right) and its corresponding Ramachandran plot (left). The high percentage of residues in favored regions confirms the quality of the structural model.</p>
                    </div>

                    <h3 class="subsection-title full-width">3.3. Molecular Docking</h3>
                    <p class="mb-4">
                        Molecular docking simulations showed strong and stable binding between the vaccine construct and the immune receptors TLR4, MHC-I, and MHC-II. The interactions involved numerous non-bonded contacts, hydrogen bonds, and salt bridges, indicating a high binding affinity. This suggests that the vaccine can be effectively recognized by antigen-presenting cells and T-cells, a critical step for initiating an immune response.
                    </p>
                    <div class="figure full-width">
                        <div class="grid grid-cols-1 sm:grid-cols-3 gap-4">
                            <img src="images/docking-tlr4.png" alt="Docked with TLR-4" class="rounded-lg w-full h-auto object-contain border">
                            <img src="images/docking-mhc1.png" alt="Docked with MHC-I" class="rounded-lg w-full h-auto object-contain border">
                            <img src="images/docking-mhc2.png" alt="Docked with MHC-II" class="rounded-lg w-full h-auto object-contain border">
                        </div>
                        <p class="figure-caption"><span class="figure-number">Figure 3.</span> Molecular docking complexes of the vaccine construct with immune receptors. From left to right: vaccine docked with TLR-4, MHC-I, and MHC-II, demonstrating favorable binding orientations.</p>
                    </div>

                    <h3 class="subsection-title full-width">3.4. Immune Simulation</h3>
                    <p class="mb-4">
                        The C-ImmSim server predicted a robust immune response following the simulated three-dose vaccination schedule. The results showed a significant primary response and a strong secondary response, characterized by elevated levels of immunoglobulins (IgM and IgG), activation of B-cell and T-cell populations, and the production of key cytokines like IFN-Î³. This indicates the vaccine's potential to induce long-lasting immunological memory.
                    </p>
                    <div class="figure full-width">
                        <img src="images/immune-simulation.png" alt="Immune Simulation Results" class="rounded-lg w-full h-auto object-contain border">
                        <p class="figure-caption"><span class="figure-number">Figure 4.</span> Predicted immune response from the C-ImmSim server. The graph shows antigen levels (black spikes) and the subsequent rise in antibody titers (colored lines), indicating a strong primary and memory response after each simulated injection.</p>
                    </div>

                    <h3 class="subsection-title full-width">3.5. Codon Optimization and In Silico Cloning</h3>
                    <p class="mb-4">
                        The vaccine's DNA sequence was successfully optimized for expression in *E. coli*, achieving a high Codon Adaptation Index (CAI) of 1.0 and an optimal GC content of 51.3%. The optimized gene was then cloned *in silico* into the pET28a(+) vector, confirming its suitability for high-level recombinant protein production in a standard laboratory expression system.
                    </p>
                    <div class="figure full-width">
                        <img src="images/in-silico-cloning.png" alt="Plasmid Map" class="rounded-lg w-full h-auto object-contain border">
                        <p class="figure-caption"><span class="figure-number">Figure 5.</span> Recombinant plasmid map showing the optimized vaccine gene cloned into the pET28a(+) expression vector. This construct is ready for experimental protein production.</p>
                    </div>
                </div>
            </section>
            
            <section id="discussion">
                <h2 class="section-title full-width">4. Discussion</h2>
                <div class="two-column">
                    <p class="mb-4">
                        The urgent need for a vaccine against Group A Streptococcus, coupled with the challenges of traditional vaccine development, highlights the value of immunoinformatics. Our study demonstrates a comprehensive *in silico* pipeline that successfully designed a promising multi-epitope vaccine candidate. By targeting conserved epitopes from two key virulence factors, M protein and FbaA, our construct is designed to overcome the challenge of M-type variability and provide broader protection.
                    </p>
                    <p class="mb-4">
                        The inclusion of a 50S ribosomal protein adjuvant is a key feature of our design, intended to stimulate a strong innate immune response, which is crucial for shaping the subsequent adaptive immunity. The favorable physicochemical properties, particularly the predicted stability and solubility, are critical for the practical aspects of vaccine manufacturing, storage, and delivery.
                    </p>
                    <p class="mb-4">
                        The high-quality 3D structure and successful docking with TLR4, MHC-I, and MHC-II provide strong theoretical support for the vaccine's mechanism of action. The ability to bind effectively to these receptors is a prerequisite for inducing both cell-mediated and humoral immunity. Furthermore, the immune simulation results align with the characteristics of an effective vaccine, predicting a strong memory response that is essential for long-term protection.
                    </p>
                    <p class="mb-4">
                        While the computational results are highly encouraging, it is crucial to acknowledge the limitations of an *in silico* study. These predictions require experimental validation. The next steps would involve synthesizing the optimized gene, expressing and purifying the recombinant protein, and then evaluating its immunogenicity and protective efficacy in preclinical animal models. Nonetheless, this study provides a robust, rationally designed candidate and a solid foundation for future experimental work.
                    </p>
                </div>
            </section>
            
            <section id="conclusion">
                <h2 class="section-title full-width">5. Conclusion</h2>
                <div class="two-column">
                    <p>
                        In conclusion, this study successfully employed a range of immunoinformatics tools to design and validate a novel multi-epitope subunit vaccine against Group A Streptococcus. The final construct is predicted to be a stable, soluble, antigenic, and non-allergenic protein capable of inducing a robust and comprehensive immune response. The computational evidence strongly suggests that this vaccine candidate has the potential to be an effective prophylactic agent against GAS infections. This work underscores the power of *in silico* methods to accelerate the development of next-generation vaccines and provides a promising candidate that is ready for experimental validation.
                    </p>
                </div>
            </section>

            <section id="references">
                <h2 class="section-title full-width">6. References</h2>
                <div class="two-column references">
                    <ol>
                        <li class="reference-item">1. Brouwer, S., Barnett, T. C., Rivera-Hernandez, T., Rohde, M., & Walker, M. J. (2016). Streptococcus pyogenes adhesion and colonization. *FEBS Letters*, 590(21), 3739-3757.</li>
                        <li class="reference-item">2. Carapetis, J. R., Steer, A. C., Mulholland, E. K., & Weber, M. (2005). The global burden of group A streptococcal diseases. *The Lancet Infectious Diseases*, 5(11), 685-694.</li>
                        <li class="reference-item">3. Vita, R., Mahajan, S., Overton, J. A., et al. (2019). The Immune Epitope Database (IEDB): 2018 update. *Nucleic Acids Research*, 47(D1), D339-D343.</li>
                        <li class="reference-item">4. Doytchinova, I. A., & Flower, D. R. (2007). VaxiJen: a server for prediction of protective antigens, tumor antigens and subunit vaccines. *BMC Bioinformatics*, 8(1), 4.</li>
                        <li class="reference-item">5. Dimitrov, I., Flower, D. R., & Doytchinova, I. (2013). AllerTOP-a server for in silico prediction of allergens. *BMC Bioinformatics*, 14(S6), S4.</li>
                        <li class="reference-item">6. Gasteiger, E., Hoogland, C., Gattiker, A., et al. (2005). Protein identification and analysis tools on the ExPASy server. In *The Proteomics Protocols Handbook* (pp. 571-607). Humana Press.</li>
                        <li class="reference-item">7. Kim, D. E., Chivian, D., & Baker, D. (2004). Protein structure prediction and analysis using the Robetta server. *Nucleic Acids Research*, 32(Web Server issue), W526-W531.</li>
                        <li class="reference-item">8. van Zundert, G. C. P., Rodrigues, J. P. G. L. M., Trellet, M., et al. (2016). The HADDOCK2. 2 Web Server: User-Friendly Integrative Modeling of Biomolecular Complexes. *Journal of Molecular Biology*, 428(4), 720-725.</li>
                        <li class="reference-item">9. Rapin, N., Lund, O., Bernaschi, M., & Castiglione, F. (2010). Computational immunology meets bioinformatics: the use of prediction tools for molecular binding in the simulation of the immune system. *PLoS ONE*, 5(4), e9862.</li>
                        <li class="reference-item">10. Grote, A., Hiller, K., Scheer, M., et al. (2005). JCat: a novel tool to adapt codon usage of a target gene to its potential expression host. *Nucleic Acids Research*, 33(Web Server issue), W526-W531.</li>
                    </ol>
                </div>
            </section>
        </main>
    </div>

    <script>
        document.getElementById('mobile-nav').addEventListener('change', function(e) {
            const section = document.querySelector(e.target.value);
            if (section) {
                section.scrollIntoView({ behavior: 'smooth' });
            }
        });

        const sections = document.querySelectorAll('section');
        const navLinks = document.querySelectorAll('.nav-link');
        const observer = new IntersectionObserver((entries) => {
            entries.forEach(entry => {
                if (entry.isIntersecting) {
                    navLinks.forEach(link => {
                        link.classList.toggle('active', link.getAttribute('href') === '#' + entry.target.id);
                    });
                }
            });
        }, { rootMargin: '-50% 0px -50% 0px' });
        sections.forEach(section => observer.observe(section));
    </script>
</body>
</html>
